Added to YB: 2026-01-14
Pitch date: 2025-11-08
ADCT [bullish]
ADC Therapeutics SA
-66.5%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States.
Market Cap
$156.4M
Pitch Price
$4.03
Price Target
N/A
Dividend
N/A
EV/EBITDA
-3.58
P/E
-1.14
EV/Sales
4.57
Sector
Biotechnology
Category
growth
Show full summary:
ADC Therapeutics SA - $ADCT
ADCT: Novel CD19-ADC Zynlonta ($70M current revenue) testing in 2L DLBCL. LOTIS-5 (Zynlonta+Rituxan) targeting 6mo mPFS vs 4mo control, delayed readout to 1H26 suggests ~9.5mo mPFS. LOTIS-7 (Zynlonta+Columvi) showed 93% ORR/87% CR in 31 pts. Success could drive $400M peak sales by 2031, 30% IRR potential vs $500M market cap.
Read full article (12 min)